Financial highlights
Operational and strategic progress
Portfolio highlights
Despite the challenges faced as a result of COVID-19, Arix portfolio companies continued to make strong clinical and operational progress during the period. Notably: Outlook - Key anticipated milestones
Data generated from our clinical pipeline will be a key driver of value and whilst clinical development is not without risk, and the recruitment of clinical trials globally has been impacted by the coronavirus pandemic, we have a number of portfolio companies approaching key milestones. In particular, we note the following anticipated milestones across our portfolio in H2 2021:
'Whilst the volatility of public companies has impacted our financial performance during the period, our focus remains on the clinical progress of these businesses. This is what we believe will drive their value in the future. Importantly, these companies are well capitalised and therefore in a strong position to reach their important clinical milestones.
'It is truly an exciting time in biotech, and we continue to see a strong pipeline of new investment opportunities across a broad range of therapeutic areas. Our focus is on building the team to identify these opportunities and support our existing portfolio. We believe our strong capital base and numerous expected value inflection points have the potential to drive transformative growth in our NAV, for the benefit of shareholders.'
Contact:
Tel: +44 (0)20 7290 1050
Email: ir@arixbioscience.com
About
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
(C) 2021 Electronic News Publishing, source